Bronchodilating activity of mequitazine.

Area of Science:

• Pharmacology
• Respiratory Medicine
• Allergy and Immunology

Background:

• Bronchoconstriction is a key feature of respiratory diseases.
• Histamine and leukotriene-C4 (LTC4) are major mediators of bronchoconstriction and allergic responses.
• Arachidonic acid metabolism, particularly thromboxane A2 (TXA2) formation, plays a role in allergic airway inflammation.

Purpose of the Study:

• To investigate the bronchodilating and antiallergic activities of mequitazine (MQ).
• To evaluate MQ's effects on bronchoconstriction induced by acetylcholine, histamine, and LTC4 in guinea pigs.
• To assess MQ's impact on arachidonic acid metabolism and TXA2 formation.

Main Methods:

• In vivo studies using guinea pigs exposed to various spasmogens.
• In vitro experiments with isolated guinea pig perfused lungs.
• Measurement of TXA2 formation and circulating TXA2 levels.
• Assessment of protection against antigen challenge in passively sensitized guinea pigs.

Main Results:

• Mequitazine (MQ) demonstrated potent protection against bronchoconstriction induced by acetylcholine, histamine, and LTC4.
• MQ inhibited the activation of arachidonic acid metabolism and TXA2 formation.
• In vivo and in vitro results showed correlation regarding histamine and LTC4-induced TXA2 release.
• MQ protected sensitized guinea pigs from antigen challenge, reducing circulating TXA2.
• MQ counteracted in vitro and in vivo effects of LTC4.

Conclusions:

• Mequitazine exhibits significant bronchodilating and antiallergic properties.
• Its efficacy may stem from direct control of histamine and muscarinic receptors and reduced eicosanoid activation.
• MQ's ability to counteract LTC4 effects enhances its therapeutic potential for allergic airway diseases.